Global Transdermal Drug Delivery Partnering 2010-2015

1. Global Transdermal Drug Delivery Partnering 2010-2015

2. Provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. -Transdermal Drug Delivery Partnering 2010-2015 report provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies. -Trends in transdermal drug delivery partnering deals -Top transdermal drug delivery deals by value -Deals listed by company A-Z, deal type, stage of development, therapy type

3. Transdermal Drug Delivery Partnering 2010-2015 provides understanding and access to the transdermal drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter transdermal drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

4. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. This report contains over 150 links to online copies of actual transdermal drug delivery deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

5. The initial chapters of this report provide an orientation of transdermal drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst Chapter 2 provides an overview of the trends in transdermal drug delivery dealmaking since 2010. Chapter 3 is the most popular chapter that includes details of average headline, upfront, milestone and royalty terms. Chapter 4 provides a review of the leading transdermal drug delivery deals since 2010. Deals are listed by headline value, most active of all biopharma companies and signed by big pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

6. Chapter 5 provides a comprehensive directory of transdermal drug delivery partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in transdermal drug delivery partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about transdermal drug delivery partnering in the research, development and commercialization of drug delivery technologies and products.

7. Report scope Transdermal Drug Delivery Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to transdermal drug delivery trends and structure of deals entered into by leading companies worldwide. This data driven report includes: -Trends in transdermal drug delivery dealmaking in the biopharma industry since 2010 -Access to summary headline, upfront, milestone and royalty data -Access to over 150 transdermal drug delivery actual deal records -The leading transdermal deals by value since 2010

8. In Transdermal Drug Delivery Partnering 2010-2015, the available deals are listed by: -Headline value -Upfront payment value -Royalty rate value -Company A-Z -Industry sector -Stage of development at signing -Deal component type -Therapy type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

9. Transdermal Drug Delivery Partnering 2010-2015 provides the reader with the following key benefits: -In-depth understanding of transdermal drug delivery deal trends since 2010 -Access to summary headline, upfront, milestone and royalty data -Comprehensive access to over 150 actual deal records entered into by the world’s biopharma companies since 2010 -Insight into key deal terms included in contracts, where disclosed -Understand the key deal terms companies have agreed in deals -Undertake due diligence to assess suitability of your proposed deal terms for partner companies

10. Table of Contents Introduction Trends in transdermal drug delivery dealmaking Transdermal drug delivery partnering over the years Big pharma transdermal drug delivery dealmaking activity Transdermal drug delivery partnering by industry type Transdermal drug delivery partnering by deal type Transdermal drug delivery partnering by disease type Average financial deal terms for transdermal drug delivery partnering Transdermal drug delivery deals by headline values Transdermal drug delivery upfront payments W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com

11. To view the full Executive Summary and Table of Contents, please visit: Global Transdermal Drug Delivery Partnering 2010-2015 Contact Us:-Call India: +91-22-27810772/73Email id : info@bharatbook.comWebsite :www.bharatbook.comOur Blog : https://www.bharatbook.com/blog/ W : www.bharatbook.com , T :  +91 22 27810772, 27810773, E :  info@bharatbook.com